TrialCancer2026

Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma.

Lisa A Kachnic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.